Our Blog
Our thoughts on the topics we care about.
FDA advisory panel recommends telavancin as last-resort drug for MRSA nosocomial pneumonia
On November 29th, 2012, the FDA's Anti-Infective Drugs Advisory Committee voted 13-2 to recommend telavancin (Vibativ®) for the treatment of nosocomial pneumonia including hospital- and ventilator-acquired pneumonia (HAP, VAP) caused by MRSA in seriously ill patients...
The Sepsis Clinical Guide news feed
The Sepsis Clinical Guide version 2.0 for iOS includes ESCAVO's News feed. Here, Sepsis app users will receive periodic news and information in the field of sepsis management, infectious disease, critical care, mobile health, and other relevant topics. We will also...
Sepsis App Giveaway During Sepsis Awareness Month!
In recognition of Sepsis Awareness Month, we will be giving away free copies of our popular Sepsis Clinical Guide app during the entire month of September. We want to put this valuable tool in the hands of as many physicians and other healthcare workers as possible,...
What is Sepsis and Why Did We Make an App for it?
Why a sepsis app? As is it often the case, it's personal. Sepsis has affected people very close to us and we wanted to do something about it. And we're not alone. Every year, over 700,000 people are affected by sepsis and over 200,000 die from it in the US. It is one...
An Update on the FDA Mobile App Guidance from the 4th Annual mHealth World Congress
During the July 25th opening session of the 4th mHealth World Congress held in Boston, a heated discussion highlighted the level of interest in the upcoming FDA mobile app guidance, and the agency's regulation of other new healthcare technologies. According to Bakul...